Research programme: nuclear-receptor-subfamily-1-group-F-member-3 antagonists - Advinus Therapeutics

Drug Profile

Research programme: nuclear-receptor-subfamily-1-group-F-member-3 antagonists - Advinus Therapeutics

Alternative Names: ROR-gamma antagonists - Advinus Therapeutics; RORγ antagonist - Advinus

Latest Information Update: 25 Jan 2016

Price : $50

At a glance

  • Originator Advinus Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Research Psoriasis

Most Recent Events

  • 25 Jan 2016 Early research in Psoriasis in India (unspecified route)
  • 25 Jan 2016 Nuclear-receptor-subfamily-1-group-F-member-3 antagonists - Advinus Therapeutics is available for licensing as of 25 Jan 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top